title: Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.
abstract: BACKGROUND
  Long-acting somatostatin analogues have been suggested as an alternative to propranolol for the prevention of variceal rebleeding.
  
  
  OBJECTIVE
  To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulated hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis.
  
  
  METHODS
  Patients were randomized to receive either lanreotide SR intramuscularly (30 mg once weekly, n=12) or propranolol (n=12) orally. Hemodynamic measurements were performed on day 0 and on day 21 after a 3-week period of drug administration, while patients received three standard oral liquid test meals. On each study day 27 PVF measurements were performed over 24 h and eight measurements of HVPG during the first postprandial period.
  
  
  RESULTS
  Propranolol was more effective than lanreotide SR in reducing baseline HVPG (-21.9 vs. -13.6%, P=0.04) and meal-stimulated HVPG (-16.6 vs. -3.8%, P=0.04). Propranolol reduced circadian PVF significantly by 9.3% (P=0.03) but not lanreotide SR.
  
  
  CONCLUSIONS
  Long-term treatment with propranolol reduced baseline and postprandial HVPG and circadian PVF, while lanreotide SR did not. The results of our study do not encourage clinical testing of lanreotide SR 30 mg for the prevention of variceal haemorrhage.
authors.affiliation: Department of Internal Medicine I, University of Bonn, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Schiedermaier
authors.forename: L
authors.initials: L
authors.lastname: Koch
authors.forename: B
authors.initials: B
authors.lastname: Stoffel-Wagner
authors.forename: G
authors.initials: G
authors.lastname: Layer
authors.forename: T
authors.initials: T
authors.lastname: Sauerbruch
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002940:Circadian Rhythm; D003692:Delayed-Action Preparations; D004932:Esophageal and Gastric Varices / Q000517:prevention & control*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D007273:Injections, Intramuscular; D008102:Liver Circulation / Q000187:drug effects*; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D017082:Portal Pressure / Q000187:drug effects; D019518:Postprandial Period; D011433:Propranolol / Q000627:therapeutic use*; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D011433:Propranolol